Nothing Special   »   [go: up one dir, main page]

ITMI20032473A1 - Farmaci in polvere contenenti un sale di tiotropio e salmeterolo xinafoato - Google Patents

Farmaci in polvere contenenti un sale di tiotropio e salmeterolo xinafoato

Info

Publication number
ITMI20032473A1
ITMI20032473A1 IT002473A ITMI20032473A ITMI20032473A1 IT MI20032473 A1 ITMI20032473 A1 IT MI20032473A1 IT 002473 A IT002473 A IT 002473A IT MI20032473 A ITMI20032473 A IT MI20032473A IT MI20032473 A1 ITMI20032473 A1 IT MI20032473A1
Authority
IT
Italy
Prior art keywords
thyotropy
salt
salmeterol xinafoate
drugs containing
drug drugs
Prior art date
Application number
IT002473A
Other languages
English (en)
Italian (it)
Inventor
Hagen Graebner
Mareke Hartig
Peter Sieger
Rainer Soyka
Michael Trunk
Michael Walz
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32404034&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ITMI20032473(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of ITMI20032473A1 publication Critical patent/ITMI20032473A1/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IT002473A 2002-12-20 2003-12-16 Farmaci in polvere contenenti un sale di tiotropio e salmeterolo xinafoato ITMI20032473A1 (it)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10259912 2002-12-20

Publications (1)

Publication Number Publication Date
ITMI20032473A1 true ITMI20032473A1 (it) 2004-06-21

Family

ID=32404034

Family Applications (1)

Application Number Title Priority Date Filing Date
IT002473A ITMI20032473A1 (it) 2002-12-20 2003-12-16 Farmaci in polvere contenenti un sale di tiotropio e salmeterolo xinafoato

Country Status (21)

Country Link
EP (1) EP1581198A1 (zh)
JP (1) JP2006516135A (zh)
KR (1) KR20050086930A (zh)
CN (1) CN1728988B (zh)
AU (1) AU2003288226B2 (zh)
BR (1) BR0317443A (zh)
CA (1) CA2510779A1 (zh)
DE (1) DE10351663A1 (zh)
EA (1) EA010588B1 (zh)
EC (1) ECSP055855A (zh)
FR (1) FR2848849B1 (zh)
HR (1) HRP20050570A2 (zh)
IT (1) ITMI20032473A1 (zh)
MX (1) MXPA05006519A (zh)
NO (1) NO20053548L (zh)
NZ (1) NZ541303A (zh)
PL (1) PL376231A1 (zh)
RS (1) RS20050484A (zh)
UA (1) UA83813C2 (zh)
WO (1) WO2004058233A1 (zh)
ZA (1) ZA200503692B (zh)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
JP4342426B2 (ja) * 2004-11-24 2009-10-14 科研製薬株式会社 イトラコナゾール経口投与用製剤
EP1959942A1 (en) * 2005-08-06 2008-08-27 Boehringer Ingelheim International GmbH Method for the treatment of dyspnea comprising combined administration of tiotropium salts and salts of salmeterol
MX2007009988A (es) 2005-12-19 2008-02-22 Sicor Inc Formas novedosas de bromuro de tiotropio y procesos para su preparacion.
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
CN101437823B (zh) 2006-05-04 2014-12-10 勃林格殷格翰国际有限公司 多晶型
DE102007036411A1 (de) 2007-07-20 2009-02-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pulverinhalator
PE20090907A1 (es) * 2007-07-21 2009-08-05 Boehringer Ingelheim Int Nuevos medicamentos pulverulentos que contienen tiotropio y salmeterol, asi como lactosa como excipiente
AR071175A1 (es) 2008-04-03 2010-06-02 Boehringer Ingelheim Int Composicion farmaceutica que comprende un inhibidor de la dipeptidil-peptidasa-4 (dpp4) y un farmaco acompanante
BRPI0916997A2 (pt) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh Inibidor de dpp-4 e seu uso
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
NZ592924A (en) 2008-12-23 2014-05-30 Boehringer Ingelheim Int Salt forms of a xanthine derivative
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
BR112012012641A2 (pt) 2009-11-27 2020-08-11 Boehringer Ingelheim International Gmbh TRATAMENTO DE PACIENTES DIABÉTICOS GENOTIPADOS COM INIBIDORES DE DPP-lVTAL COMO LINAGLIPTINA
MX341025B (es) 2010-05-05 2016-08-04 Boehringer Ingelheim Int Gmbh * Terapia de combinacion.
ES2802243T3 (es) 2010-06-24 2021-01-18 Boehringer Ingelheim Int Terapia para la diabetes
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
EP3517539B1 (en) 2011-07-15 2022-12-14 Boehringer Ingelheim International GmbH Substituted dimeric quinazoline derivative, its preparation and its use in pharmaceutical compositions for the treatment of type i and ii diabetes
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
WO2013171167A1 (en) 2012-05-14 2013-11-21 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
WO2015128453A1 (en) 2014-02-28 2015-09-03 Boehringer Ingelheim International Gmbh Medical use of a dpp-4 inhibitor
KR101748796B1 (ko) * 2015-09-30 2017-06-19 한미약품 주식회사 활성성분의 전달량이 향상된 흡입용 캡슐제
AU2017276758A1 (en) 2016-06-10 2018-11-08 Boehringer Ingelheim International Gmbh Combinations of Linagliptin and metformin
MX2021005582A (es) * 2018-11-13 2021-06-30 Cocrystal Pharma Inc Formulaciones de terapias contra la gripe.

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1056974C (zh) * 1992-02-11 2000-10-04 格拉克索公司 适宜于微粒化的药物材料的制备方法
AU1229892A (en) * 1992-02-11 1993-09-03 Glaxo Group Limited Benzenedimethanol derivative suitable for micronisation
GB9313650D0 (en) * 1993-07-01 1993-08-18 Glaxo Group Ltd Method and apparatus for the formation of particles
DE19921693A1 (de) * 1999-05-12 2000-11-16 Boehringer Ingelheim Pharma Neuartige Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika
UA75375C2 (en) * 2000-10-12 2006-04-17 Boehringer Ingelheim Pharma Method for producing powdery preparations for inhaling
DE10056104A1 (de) * 2000-11-13 2002-05-23 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Tiotropiumsalzen und Salzen des Salmeterols
DE10104367A1 (de) * 2001-02-01 2002-08-08 Boehringer Ingelheim Pharma Betamimetika enthaltende Arzneimittelkompositionen mit geringeren Nebenwirkungen
DE10130371A1 (de) * 2001-06-23 2003-01-02 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika, Corticosteroiden und Betamimetika
JP2004537377A (ja) * 2001-08-09 2004-12-16 グラクソ　グループ　リミテッド 製薬組成物を有する吸入装置
JP2005504076A (ja) * 2001-09-14 2005-02-10 ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト 新規な吸入用医薬組成物

Also Published As

Publication number Publication date
UA83813C2 (ru) 2008-08-26
CA2510779A1 (en) 2004-07-15
NO20053548L (no) 2005-09-02
EP1581198A1 (de) 2005-10-05
PL376231A1 (en) 2005-12-27
EA200500902A1 (ru) 2006-02-24
EA010588B1 (ru) 2008-10-30
DE10351663A1 (de) 2004-07-01
MXPA05006519A (es) 2005-08-26
AU2003288226A1 (en) 2004-07-22
CN1728988A (zh) 2006-02-01
NZ541303A (en) 2008-11-28
KR20050086930A (ko) 2005-08-30
CN1728988B (zh) 2010-04-28
BR0317443A (pt) 2005-11-16
JP2006516135A (ja) 2006-06-22
ZA200503692B (en) 2006-10-25
FR2848849A1 (fr) 2004-06-25
ECSP055855A (es) 2005-11-22
RS20050484A (en) 2007-11-15
WO2004058233A1 (de) 2004-07-15
HRP20050570A2 (en) 2006-07-31
AU2003288226B2 (en) 2010-01-07
FR2848849B1 (fr) 2007-01-05

Similar Documents

Publication Publication Date Title
ITMI20032473A1 (it) Farmaci in polvere contenenti un sale di tiotropio e salmeterolo xinafoato
ATE401887T1 (de) Medikament enthaltend ein hochaktives langwirkendes beta-2-agonist in verbindung mit anderen wirkstoffen
DK1545662T3 (da) Lægemiddelindgivelsessystem
IS7946A (is) Lyf
CY2011003I2 (el) Φαρμακευτικα προϊοντα σε διαλυμα που περιεχουν αντισωμα
EP1682538A4 (en) BIARYL-ASSOCIATED HYDROXAMATE: PREPARATION AND PHARMACEUTICAL APPLICATIONS
PL359321A1 (en) New salt perindopryl and pharmaceutical composunds containing it
IL176248A0 (en) N-substituted-n-sulfonylaminocyclopropane compounds and pharmaceutical use thereof
DK1467789T3 (da) Lægemiddeldispenser
NO20054681D0 (no) Farmasoytiske produkter
DE602004026719D1 (de) Ür tablette
EP1898922A4 (en) MEDICINE OR IMPROVED PHARMACEUTICAL COMPOUNDS AND PREPARATION THEREOF
ATE359064T1 (de) Pharmazeutische tramadolsalze
DK1620118T3 (da) Reversible pegylerede lægemidler
DK1562573T3 (da) Farmaceutiske pellets omfattende tamsulosin og en fremgangsmåde til fremstilling deraf
ZA200602260B (en) A pharmaceutical composition comprising a P2X7 receptor antagonist and a nonsteroidal anti-inflammatory drug
DE602004016967D1 (de) Flüssige pharmazeutische palonosetronformulierungen
ZA200701059B (en) Pharmaceutical dosage forms comprising a low-solubllity drug and a polymer
NO20055173D0 (no) Farmasoytisk kombinasjonsblanding omfattende modafinil og et annet legemiddel
ATE551051T1 (de) Orales arzneimittelabgabesystem
DE60328119D1 (de) Pharmazeutische zubereitungen enthaltend modafinil
ATE524186T1 (de) Pharmazeutische kombinationen bestehend aus meloxicam, tramadol und paracetamol
FR2870539B1 (fr) Nouvelles methodes et medicaments
DK1849468T3 (da) Farmaceutisk sammensætning omfattende roflumilast og levocetirizin
AU2003257982A8 (en) Pharmaceutical dosage form capable of maintaining stable dissolution profile upon storage